Apollomics is a biopharmaceutical company focused on discovering and developing mono- and combination therapies that leverage the immune system to target specific molecular pathways in cancer treatment. The company aims to provide effective options for patients who have exhausted existing treatment alternatives, improving their clinical outcomes.
Funding
$23.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients exhaust standard treatment options, leaving them with limited alternatives and a need for therapies that can improve their clinical outcomes. Current cancer treatments may not effectively target specific molecular pathways or fully leverage the body's immune system to combat the disease.
Solution
Apollomics is developing mono- and combination therapies designed to harness the immune system and target specific molecular pathways involved in cancer progression. Their approach focuses on identifying and developing oncology therapies that can be combined with existing treatments to enhance efficacy. By basing clinical trials on mechanistic and scientific rationale, Apollomics aims to provide more effective treatment options for patients with limited alternatives. The company's goal is to improve clinical benefits and ultimately save the lives of cancer patients.
Target Audience
The primary target audience includes cancer patients who have exhausted existing treatment options and are seeking alternative therapies, as well as oncologists looking for innovative treatment approaches.
Features
- Development of mono-therapies targeting specific molecular pathways in cancer.
- Creation of combination therapies designed to work synergistically with other cancer treatments.
- Focus on leveraging the immune system to fight cancer.
- Clinical trials based on sound mechanistic and scientific rationale.